Morgan Stanley maintained Pfizer (NYSE: PFE) with a Overweight and raised the price target from $27.00 to $31.00. Morgan Stanley noted, "Pfizer's FCF yield is attractive at 8%. Raising PT from $27 to $31 based upon greater long-term pipeline contribution and thus more optimistic DCF (changed terminal growth from -3% to -2%).